☆ 4.3 Letter

Interferon β1a treatment does not influence serum Epstein-Barr virus antibodies in patients with multiple sclerosis

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Multidisciplinary Sciences

Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM

Tobias Lanz et al.

Summary: Multiple sclerosis (MS) is an autoimmune disease where autoreactive lymphocytes attack the central nervous system. Epstein-Barr virus (EBV) infection has been linked to MS, with molecular mimicry between EBV nuclear antigen 1 (EBNA1) and central nervous system protein GlialCAM. EBNA1 immunization exacerbates disease in MS mouse models and anti-EBNA1 and anti-GlialCAM antibodies are prevalent in MS patients, providing a mechanistic link between MS and EBV and guiding the development of new MS therapies.

NATURE (2022)

添加到收藏夹

Editorial Material Pharmacology & Pharmacy

Longitudinal Analysis Suggests Epstein--Barr as Cause of Multiple Sclerosis

[Anonymous]

CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)

添加到收藏夹

Article Clinical Neurology

Effect of ocrelizumab on leptomeningeal inflammation and humoral response to Epstein-Barr virus in multiple sclerosis. A pilot study

Robert Zivadinov et al.

Summary: Ocrelizumab treatment is safe and effective for patients with multiple sclerosis, reducing brain volume loss and possibly decreasing humoral response to Epstein-Barr virus. However, its effect on leptomeningeal inflammation is not significant.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2022)

添加到收藏夹

Letter Clinical Neurology

Revisiting the antiviral theory to explain interferon-beta's effectiveness for relapsing multiple sclerosis

Nahad Sedaghat et al.

Summary: Treatment with interferon-beta (IFN beta) was initially considered for multiple sclerosis (MS) due to epidemiological data suggesting a viral etiology. However, the mechanism of action of IFN beta, which relies on anti-inflammatory mechanisms, does not explain its ineffectiveness for disease progression in progressive forms of MS. New evidence linking the Epstein-Barr virus (EBV) and other herpesviruses to MS onset/relapse may call for a reconsideration of the antiviral theory behind IFN beta's mechanism of action.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2022)

添加到收藏夹

Article Clinical Neurology

Serum IgG levels to Epstein-Barr and measles viruses in patients with multiple sclerosis during natalizumab and interferon beta treatment

Linn Persson Berg et al.

Summary: Patients with multiple sclerosis (MS) show higher levels of IgG reactivity to EBVgp350 and MeV N-CORE compared to healthy controls, with a decline in reactivity observed during natalizumab treatment. All MS patients were EBV IgG seropositive, indicating the potential role of EBV in the pathogenesis of MS.

BMJ NEUROLOGY OPEN (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis

Kjetil Bjornevik et al.

Summary: This study suggests that multiple sclerosis may be caused by Epstein-Barr virus, with no direct association with other viral infections. These findings provide clues to the primary cause of MS.

SCIENCE (2022)

添加到收藏夹

Article Clinical Neurology

EBNA-1 titer gradient in families with multiple sclerosis indicates a genetic contribution

Julia Y. Mescheriakova et al.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2020)

添加到收藏夹

Article Clinical Neurology

Teriflunomide's effect on humoral response to Epstein-Barr virus and development of cortical gray matter pathology in multiple sclerosis

Robert Zivadinov et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2019)

添加到收藏夹

Article Clinical Neurology

Vitamin D, HLA-DRB1 and Epstein-Barr virus antibody levels in a prospective cohort of multiple sclerosis patients

S. Wergeland et al.

EUROPEAN JOURNAL OF NEUROLOGY (2016)

添加到收藏夹

Article Cell Biology

Interferon-β therapy specifically reduces pathogenic memory B cells in multiple sclerosis patients by inducing a FAS-mediated apoptosis

Fabiana Rizzo et al.

IMMUNOLOGY AND CELL BIOLOGY (2016)

添加到收藏夹

Article Clinical Neurology

Antibodies to Epstein-Barr virus and MRI disease activity in multiple sclerosis

Silje Kvistad et al.

MULTIPLE SCLEROSIS JOURNAL (2014)

添加到收藏夹

Article Clinical Neurology

Multiple sclerosis therapy and Epstein-Barr virus antibody titres

Joel Raffel et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2014)

添加到收藏夹

Article Virology

Comparison of two commercial ELISA systems for evaluating anti-EBNA1 IgG titers

Ruth Dobson et al.

JOURNAL OF MEDICAL VIROLOGY (2013)

添加到收藏夹

Article Clinical Neurology

ω-3 Fatty Acid Treatment in Multiple Sclerosis (OFAMS Study) A Randomized, Double-Blind, Placebo-Controlled Trial

Oivind Torkildsen et al.

ARCHIVES OF NEUROLOGY (2012)

添加到收藏夹

Article Clinical Neurology

EBV-specific immune responses in patients with multiple sclerosis responding to IFNβ therapy

Manuel Comabella et al.

MULTIPLE SCLEROSIS JOURNAL (2012)

添加到收藏夹

Article Clinical Neurology

Vitamin D and disease activity in multiple sclerosis before and during interferon-β treatment

Kristin I. Loken-Amsrud et al.

NEUROLOGY (2012)

添加到收藏夹

Article Clinical Neurology

Interferon-β mechanisms of action in multiple sclerosis

Suhayl Dhib-Jalbut et al.

NEUROLOGY (2010)

添加到收藏夹

Article Immunology

Antibodies to specific EBNA-1 domains and HLA DRB1*1501 interact as risk factors for multiple sclerosis

Peter Sundstrom et al.

JOURNAL OF NEUROIMMUNOLOGY (2009)

添加到收藏夹

Article Clinical Neurology

Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI

R. A. Farrell et al.

NEUROLOGY (2009)

添加到收藏夹

Review Microbiology

Antiviral actions of interferons

CE Samuel

CLINICAL MICROBIOLOGY REVIEWS (2001)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.